Profit vs Purpose: The Duel Begins

Kurt Graves had just heard from multiple investors in Intarcia Therapeutics, the pharmaceutical firm he runs, asking him a single question: Why wasn’t he putting Intarcia up for sale?

Continue reading the article from Russell Pearlman on Korn Ferry Institute here.

Leave a Reply

Your email address will not be published.